HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark Lebwohl Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

6/2022Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis.
6/2022Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting.
5/2022Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials.
4/2022Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
3/2022A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17.
1/2022Long-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics.
1/2022International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.
1/2022Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM Study.
11/2021Three-year U.S. pharmacovigilance report of brodalumab.
10/2021A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark Lebwohl Research Topics

Disease

152Psoriasis (Pustulosis Palmaris et Plantaris)
06/2022 - 05/2002
14Psoriatic Arthritis
04/2022 - 10/2007
14Atopic Dermatitis (Atopic Eczema)
01/2019 - 04/2003
13Neoplasms (Cancer)
11/2021 - 03/2004
11Skin Diseases (Skin Disease)
03/2022 - 06/2003
10Actinic Keratosis
02/2017 - 10/2002
9Vitiligo
12/2022 - 07/2004
9Infections
01/2022 - 06/2003
7Atrophy
12/2018 - 04/2003
6Pain (Aches)
02/2021 - 07/2015
6Pruritus (Itching)
11/2020 - 10/2007
6Acne Vulgaris
11/2020 - 04/2002
6Rheumatoid Arthritis
04/2017 - 07/2003
5Erythema
12/2018 - 02/2002
5Inflammation (Inflammations)
09/2018 - 10/2002
5Squamous Cell Carcinoma (Epidermoid Carcinoma)
06/2018 - 02/2002
4Body Weight (Weight, Body)
05/2022 - 11/2003
4Diarrhea
02/2021 - 08/2017
4Nausea
02/2021 - 08/2017
4Headache (Headaches)
02/2021 - 08/2017
4Pseudoxanthoma Elasticum (Gronblad Strandberg Syndrome)
11/2019 - 11/2003
4Skin Neoplasms (Skin Cancer)
03/2012 - 05/2004
4Carcinogenesis
08/2006 - 02/2002
3Fatigue
02/2021 - 01/2019
3COVID-19
01/2021 - 01/2020
3Vomiting
07/2020 - 08/2017
3Herpes Zoster
09/2019 - 10/2007
3Nasopharyngitis
02/2018 - 01/2016
3Crohn Disease (Crohn's Disease)
01/2018 - 04/2010
3Rosacea (Acne Rosacea)
01/2018 - 07/2003
2Ankylosing Spondylitis
04/2022 - 04/2017
2Oral Candidiasis (Thrush)
03/2022 - 01/2021
2Injection Site Reaction
02/2021 - 02/2020
2Neutropenia
02/2021 - 10/2015
2Communicable Diseases (Infectious Diseases)
01/2021 - 12/2020
2Granuloma Annulare
07/2020 - 01/2016

Drug/Important Bio-Agent (IBA)

21Biological ProductsIBA
06/2022 - 08/2003
18Ointments (Pastes)IBA
01/2017 - 11/2002
17Ustekinumab (CNTO 1275)FDA Link
06/2022 - 05/2008
16calcipotriene (calcipotriol)FDA LinkGeneric
05/2021 - 11/2002
16Adrenal Cortex Hormones (Corticosteroids)IBA
11/2020 - 05/2002
15Etanercept (Enbrel)FDA Link
05/2022 - 07/2005
13secukinumabIBA
06/2022 - 09/2013
13Interleukin-17 (Interleukin 17)IBA
03/2022 - 07/2014
13Monoclonal AntibodiesIBA
06/2020 - 11/2002
12brodalumabIBA
01/2022 - 10/2015
11betamethasone-17,21-dipropionate (betamethasone dipropionate)FDA LinkGeneric
05/2021 - 01/2013
11SteroidsIBA
04/2021 - 07/2003
10Methotrexate (Mexate)FDA LinkGeneric
01/2022 - 07/2005
9Tacrolimus (Prograf)FDA LinkGeneric
06/2020 - 04/2003
8Immunoglobulin A (IgA)IBA
06/2022 - 03/2016
8Adalimumab (Humira)FDA Link
06/2022 - 03/2008
8CytokinesIBA
03/2022 - 11/2004
8Alefacept (Amevive)FDA Link
03/2010 - 03/2003
7InterleukinsIBA
04/2022 - 05/2008
7Tumor Necrosis Factor InhibitorsIBA
09/2018 - 07/2005
7ixekizumabIBA
08/2018 - 12/2014
7Cyclosporine (Ciclosporin)FDA LinkGeneric
06/2018 - 03/2004
6halobetasol (ulobetasol)FDA LinkGeneric
12/2018 - 11/2002
6Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2018 - 10/2007
6AerosolsIBA
06/2017 - 02/2016
5Pharmaceutical PreparationsIBA
10/2021 - 06/2008
5Interleukin-23 (Interleukin 23)IBA
01/2019 - 04/2010
5Infliximab (Remicade)FDA Link
12/2018 - 01/2008
5tazarotene (Tazorac)FDA Link
12/2018 - 04/2002
5RetinoidsIBA
01/2018 - 09/2002
53-ingenyl angelateIBA
02/2017 - 03/2012
5efalizumab (Raptiva)FDA Link
06/2009 - 11/2003
5Ficusin (Psoralen)IBA
06/2009 - 02/2002
5Clobetasol (Clobetasol Propionate)FDA LinkGeneric
06/2008 - 05/2002
5AcitretinFDA Link
05/2008 - 09/2002
4apremilastIBA
07/2020 - 08/2017
4Interleukin-12 (IL 12)IBA
06/2018 - 02/2007
4afamelanotideIBA
07/2015 - 01/2013
4Calcitriol (Calcijex)FDA LinkGeneric
02/2012 - 09/2003
4pimecrolimus (Elidel)FDA Link
07/2011 - 11/2004
3FumaratesIBA
01/2022 - 09/2009
3Mycophenolic Acid (Cellcept)FDA LinkGeneric
06/2020 - 06/2009
3Prostaglandins AIBA
01/2020 - 04/2004
3Biomarkers (Surrogate Marker)IBA
01/2019 - 01/2014
3Imiquimod (Aldara)FDA LinkGeneric
01/2009 - 10/2002
3Benzo(a)pyreneIBA
03/2008 - 04/2003
3GenisteinIBA
08/2006 - 02/2002
3IsoflavonesIBA
08/2006 - 02/2002
2risankizumabIBA
06/2022 - 01/2018
2ruxolitinibIBA
01/2022 - 11/2020
2Interleukin-17 ReceptorsIBA
11/2021 - 02/2021
2guselkumabIBA
08/2021 - 01/2018
2bimekizumabIBA
01/2021 - 01/2021
2Isotretinoin (Accutane)FDA LinkGeneric
11/2020 - 11/2006
2tofacitinibIBA
06/2020 - 08/2017
2Thioguanine (Tioguanine)FDA Link
06/2020 - 09/2009
2Leflunomide (Arava)FDA LinkGeneric
06/2020 - 09/2009
2Hydroxyurea (Hydrea)FDA LinkGeneric
06/2020 - 09/2009
2MagnesiumIBA
11/2019 - 01/2019

Therapy/Procedure

71Therapeutics
06/2022 - 04/2002
18Biological Therapy
05/2022 - 04/2003
14Phototherapy (Light Therapy)
12/2022 - 06/2006
5Excimer Lasers
09/2019 - 07/2004
2Critical Care (Surgical Intensive Care)
01/2021 - 12/2020